FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Darren Veach

Research Profile

Chemicals & Drugs

Living Beings

Mouse

Phenomena

Phosphorylation

Anatomy

Disorders

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Physiology

Co-author Network

Publications

TOP 3
Miriam Benezra; Dolares Hambardzumyan; Eric C Holland; Steven M Larson; Valerie Longo; Tatsuya Ozawa; Oula Penate-Medina; Evan Phillips; Nagavarakishore Pillarsetty; Peter Smith-Jones; Darren R Veach; Pat B Zanzonico; Michelle S Bradbury
Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model.
Benedikt Bosbach; Elisa de Stanchina; Shayu Deshpande; Katia Manova-Todorova; Malcolm A S Moore; Ferdinand Rossi; Joseph M Scandura; Jae-Hung Shieh; Gunhild Sommer; Darren R Veach; Cristina R Antonescu; Peter Besmer
Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor.
Mark P S Dunphy; Jason Lewis; Nagavarakishore Pillarsetty; Romel Somwar; Darren R Veach; Pat Zanzonico; Steven Larson
Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Darren Veach (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Miriam Benezra; Dolares Hambardzumyan; Eric C Holland; Steven M Larson; Valerie Longo; Tatsuya Ozawa; Oula Penate-Medina; Evan Phillips; Nagavarakishore Pillarsetty; Peter Smith-Jones; Darren R Veach; Pat B Zanzonico; Michelle S Bradbury
Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model.
Neoplasia (New York, N.Y.) 2012;14(12):1132-43.
2012: Benedikt Bosbach; Elisa de Stanchina; Shayu Deshpande; Katia Manova-Todorova; Malcolm A S Moore; Ferdinand Rossi; Joseph M Scandura; Jae-Hung Shieh; Gunhild Sommer; Darren R Veach; Cristina R Antonescu; Peter Besmer
Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor.
Proceedings of the National Academy of Sciences of the United States of America 2012;109(34):E2276-83.
2012: Mark P S Dunphy; Jason Lewis; Nagavarakishore Pillarsetty; Romel Somwar; Darren R Veach; Pat Zanzonico; Steven Larson
Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging.
Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 2012;14(1):25-31.
2010: Ferdinand Rossi; Yasemin Yozgat; Elisa de Stanchina; Darren R Veach; Bayard Clarkson; Katia Manova-Todorova; Filippo G Giancotti; Cristina R Antonescu; Peter Besmer
Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib.
Molecular cancer research : MCR 2010;8(9):1271-83.
2010: Mikhail Doubrovin; Tatiana Kochetkova; Elmer B Santos; Darren R Veach; Peter Smith-Jones; Nagavarakishore Pillarsetty; Julius Balatoni; William G Bornmann; Juri G Gelovani; Steven M Larson
(124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2010;51(1):121-9.
2009: Christophe Antczak; Darren R Veach; Christina N Ramirez; Maria A Minchenko; David Shum; Paul A Calder; Mark Frattini; Bayard Clarkson; Hakim Djaballah
Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors.
Bioorganic & medicinal chemistry letters 2009;19(24):6872-6.
2009: Tianhua Guo; Mihai Hajdu; Narasimhan P Agaram; Hiroko Shinoda; Darren R Veach; Bayard Clarkson; ROBERT G MAKI; Samuel Singer; Ronald P DeMatteo; Peter Besmer; Cristina R Antonescu
Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(22):6862-70.
2007: Sizhi Paul Gao; Kevin G Mark; Kenneth Leslie; William Pao; Noriko Motoi; William L Gerald; William D Travis; William G Bornmann; Darren R Veach; Bayard Clarkson; Jacqueline F Bromberg
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.
The Journal of clinical investigation 2007;117(12):3846-56.
2007: Darren R Veach; Mohammad Namavari; Nagavarakishore Pillarsetty; Elmer B Santos; Tatiana Beresten-Kochetkov; Caryl L Lambek; Blesida J Punzalan; Christophe Antczak; Peter Smith-Jones; Hakim Djaballah; Bayard Clarkson; Steven M Larson
Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
Journal of medicinal chemistry 2007;50(23):5853-7.
2007: Tianhua Guo; Narasimhan P Agaram; Grace C Wong; Glory Hom; David R D'Adamo; ROBERT G MAKI; Gary K Schwartz; Darren R Veach; Bayard Clarkson; Samuel Singer; Ronald P DeMatteo; Peter Besmer; Cristina R Antonescu
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(16):4874-81.
2007: Cristina R Antonescu; Klaus J Busam; Todd D Francone; Grace C Wong; Tianhua Guo; Narasimhan P Agaram; Peter Besmer; Achim Jungbluth; Mark I Gimbel; Chin-Tung Chen; Darren R Veach; Bayard Clarkson; Philip B Paty; Martin R Weiser
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.
International journal of cancer. Journal international du cancer 2007;121(2):257-64.
2006: Xiquan Liang; Mahbod Hajivandi; Darren R Veach; David Wisniewski; Bayard Clarkson; Marilyn D Resh; Marshall pope
Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells.
Proteomics 2006;6(16):4554-64.
2006: Mohammad Azam; Valentina Nardi; William C Shakespeare; Chester A Metcalf; Regine S Bohacek; Yihan Wang; Raji Sundaramoorthi; Piotr Sliz; Darren R Veach; William G Bornmann; Bayard Clarkson; David C Dalgarno; Tomi K Sawyer; George Q Daley
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(24):9244-9.
2006: Hans-Guido Wendel; Elisa de Stanchina; Enriqué Cepero; Sagarika Ray; Michael Emig; Jordan S Fridman; Darren R Veach; William G Bornmann; Bayard Clarkson; W Richard McCombie; Scott C Kogan; Andreas Hochhaus; Scott W Lowe
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(19):7444-9.
2005: Patrick Reeves; Bettina Bommarius; Sarah L Lebeis; Shannon McNulty; Jens Christensen; Alyson Swimm; Ann Chahroudi; Rahul Chavan; Mark B Feinberg; Darren R Veach; William G Bornmann; Melanie Sherman; Daniel Kalman
Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases.
Nature medicine 2005;11(7):731-9.
2005: Nicholas C Wolff; Darren R Veach; William P Tong; William G Bornmann; Bayard Clarkson; Robert L Ilaria
PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Blood 2005;105(10):3995-4003.
2005: Darren R Veach; Mohammad Namavari; Tatiana Beresten; Julius Balatoni; Maria Minchenko; Hakim Djaballah; Ronald D Finn; Bayard Clarkson; Juri G Gelovani; William G Bornmann; Steven M Larson
Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors.
Nuclear medicine and biology 2005;32(4):313-21.
2005: Nikolas von Bubnoff; Darren R Veach; Heiko van der Kuip; Walter Aulitzky; Jana Sänger; Petra Seipel; William G Bornmann; Christian Peschel; Bayard Clarkson; Justus Duyster
A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.
Blood 2005;105(4):1652-9.
2004: Xinzhu Deng; E Randal Hofmann; Alberto Villanueva; Oliver Hobert; Paola Capodieci; Darren R Veach; Xianglei Yin; Luis Campodonico; Athanasios Glekas; Carlos Cordon-Cardo; Bayard Clarkson; William G Bornmann; Zvi Fuks; Michael O. Hengartner; Richard Kolesnick
Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation.
Nature genetics 2004;36(8):906-12.
2004: Alex J Tipping; S Baluch; David J Barnes; Darren R Veach; B M Clarkson; William G Bornmann; François-Xavier Mahon; John M Goldman; Junia V Melo
Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.
Leukemia 2004;18(8):1352-6.
2004: Alyson Swimm; Bettina Bommarius; Yue Li; David Cheng; Patrick Reeves; Melanie Sherman; Darren R Veach; William G Bornmann; Daniel Kalman
Enteropathogenic Escherichia coli use redundant tyrosine kinases to form actin pedestals.
Molecular biology of the cell 2004;15(8):3520-9.
2003: William Netzer; Fei Dou; Dongming Cai; Darren R Veach; Stephanie Jean; Yueming Li; William G Bornmann; Bayard Clarkson; Huaxi Xu; Paul Greengard
Gleevec inhibits beta-amyloid production but not Notch cleavage.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(21):12444-9.
2003: William M Spees; Guangli Yang; Darren R Veach; Maria Belen Rubio; Jason A Koutcher; William G Bornmann
A fluorine-labeled methotrexate as a probe for monitoring tumor antifolate pharmacokinetics: synthesis, in vitro cytotoxicity, and pilot in vivo 19F magnetic resonance spectra.
Molecular cancer therapeutics 2003;2(10):933-9.
2003: Nikolas von Bubnoff; Darren R Veach; W Todd Miller; Wanqing Li; Jana Sänger; Christian Peschel; William G Bornmann; Bayard Clarkson; Justus Duyster
Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.
Cancer research 2003;63(19):6395-404.
2003: Keith Q Tanis; Darren R Veach; Henry S Duewel; William G Bornmann; Anthony J Koleske
Two distinct phosphorylation pathways have additive effects on Abl family kinase activation.
Molecular and cellular biology 2003;23(11):3884-96.
2003: Bhushan Nagar; Oliver Hantschel; Matthew Adam Young; Klaus Scheffzek; Darren R Veach; William G Bornmann; Bayard Clarkson; Giulio Superti-Furga; John Kuriyan
Structural basis for the autoinhibition of c-Abl tyrosine kinase.
Cell 2003;112(6):859-71.
2002: David Wisniewski; Caryl L Lambek; Chongyuan Liu; Annabel Strife; Darren R Veach; Bhushan Nagar; Matthew Adam Young; Thomas Schindler; William G Bornmann; Joseph R Bertino; John Kuriyan; Bayard Clarkson
Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.
Cancer research 2002;62(15):4244-55.
2002: Bhushan Nagar; William G Bornmann; Patricia Pellicena; Thomas Schindler; Darren R Veach; W Todd Miller; Bayard Clarkson; John Kuriyan
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
Cancer research 2002;62(15):4236-43.
2001: R M Hofmann; GJ Cotton; Emmanuel J Chang; E Vidal; Darren R Veach; William G Bornmann; Tom W Muir
Fluorescent monitoring of kinase activity in real time: development of a robust fluorescence-based assay for Abl tyrosine kinase activity.
Bioorganic & medicinal chemistry letters 2001;11(24):3091-4.